Redactions with respect to certain portions hereof denoted with “***” Execution Date: August 27, 2019 Effective Date: August 20, 2019 SUBLICENSE AGREEMENT BETWEEN MAYNE PHARMA INTERNATIONAL PTY LTD INHIBITOR THERAPEUTICS, INC.Sublicense Agreement • November 7th, 2019 • Inhibitor Therapeutics, Inc. • Services-commercial physical & biological research • Maryland
THIS SUBLICENSE AGREEMENT (this “Agreement”) is executed on August 27, 2019 and entered into effective as of August 20, 2019 by and between MAYNE PHARMA INTERNATIONAL PTY LTD, ABN 88 007 870 984, an Australian body corporate having an address at 1538 Main North Road, Salisbury South, SA 5106, Australia (“Mayne Pharma”), and INHIBITOR THERAPEUTICS, , INC. (formerly known as HedgePath Pharmaceuticals, Inc.), a company incorporated in Delaware having an address at 4830 W. Kennedy Blvd, Suite 600, Tampa, Florida, 33609, United States (“INTI”) with respect to the following:
